肿瘤药学2018，Vol.8Issue(6)：915-918,4.DOI:10.3969/j.issn.2095-1264.2018.06.17
吉西他滨联合顺铂化疗对非小细胞肺癌患者ERCC1基因表达的影响
Effect of Gemcitabine Combined with Cisplatin on the Expression of ERCC1 in Patients with Non-small Cell Lung Cancer★
陈方姗 1刘蔚 1黄进 1徐山凌 1李阔1
作者信息
- 1. 西南医科大学附属中医医院肿瘤科,四川 泸州,646000
- 折叠
摘要
Abstract
Objective To investigate efficacy of gemcitabine plus cisplatin (GP) chemotherapy and its correlation with the expression of excision repair cross-complementing gene 1 (ERCC1) in non-small cell lung cancer. Methods The firstly confirmed 50 cases of patients with advanced non small cell lung cancer in our hospital were select out for this study. Real-time fluorescent quantitative PCR was applied to detect the ERCC1 expression. According to the detection results, there were 28 cases in ERCC1(+) group and 22 cases in ERCC1(-) group. All patients were treated with gemcitabine combined with cisplatin chemotherapy. All were followed up to analyze the correlation be-tween ERCC1 expression and drug resistance of non-small cell lung cancer. Results In ERCC1(+) group, GP chemotherapy response rate was 32%, while it was 50% in ERCC1(-) group; the difference between the two groups was statistically significant (P<0.05). The ERCC1(+) expression rate was 56%. The ERCC1 expression showed a significant correlation with smoking (P<0.05), but no correlation with gender, age, histological type, clinical stage and lymph node metastasis (P>0.05). In the ERCC1(+) group, the 1- and 3-year survival rates were respectively 49.01% and 23.42%. Whereas in ERCC1(-) group, the 1- and 3-year survival rates were 67.06% and 38.57% respectively. The ERCC1(-) group had significantly higher survival rate than ERCC1(+) group (P<0.05). The median survival time was 18 months in ERCC1(+) group, but it was 30 months in ERCC1(-) group; there was significant difference between two groups (P=0.0339). After treat-ment, patients of ERCC1(-) group had higher levels of CD3, CD4, CD8 and CD4/CD8 than those of ERCC1(+) group (P<0.05). Conclusion Platinum-based chemotherapy had a good benefit to the prognosis of non-small cell lung cancer patients with low expression of ERCC1.关键词
非小细胞肺癌/顺铂/ERCC1/耐药Key words
NSCLC/Cisplatin/ERCC1/Drug Resistance分类
医药卫生引用本文复制引用
陈方姗,刘蔚,黄进,徐山凌,李阔..吉西他滨联合顺铂化疗对非小细胞肺癌患者ERCC1基因表达的影响[J].肿瘤药学,2018,8(6):915-918,4.
